期刊文献+

^(186)Re(Sn)-HEDP的制备及色层分析研究 被引量:4

PREPARATION OF  ̄(186)Re(Sn)-HEDP AND THE COMPARATIVE ANALYSES OF CHROMATOGRAPHICAL METHODS
下载PDF
导出
摘要 介绍 ̄(186)Re(Sn)-HEDP的制备工艺,重点研究由SephadexG-75和国产717型阴离子交换树脂组成的复合柱进行放化纯度分析的方法。用高压液相色谱对原料、纯化前后的 ̄(186)Re(Sn)-HEDP作UV吸收和对应放射性峰比对分析,实验结果表明,HPLC色谱图与文献引用的 ̄(99)Tc-HEDP、 ̄(186)Re(Sn)-HEDP的HPLC色谱图基本一致,产品中杂质含量远比文献中的同类产品要少。原来采用的生理盐水和丙酮纸色层分析体系并不能进行放化纯度的分析测定,尤其是在还原不充分、标记率不高的情况下。而复合柱色层却能快速、简便地进行放化纯度的测定,并能对产品进行纯化。经动物实验证明,纯化的 ̄(186)Re(Sn)-HEDP在动物体内分布较理想,小鼠的甲状腺、肝等器官的吸收比未经纯化的 ̄(186)Rn(Sn)-HEDP明显减少。 The labeling technology of  ̄(186)Re(Sn)-HEDP is described, and a complex column(in SephadexG-75 and 717# resin)chromatographic analysis method is studied. Meanwhile, the comparative analyses, on the UV absorption and radioactive determination of purified  ̄(186)Re(Sn)-HEDP and unpurified ̄(186)Re(Sn)-HEDP are carried out by HPLC. The relative HPLC spectrums to be obtained are basicallycorrespondent with the spectrums of  ̄(99)Tc ̄m-HEDP、  ̄(186)Re(Sn)-HEDP quoted from reference, and contamination contents of our product are also less than that one. Experimental results demonstrate thatdouble-paper stripe chromatographic system are unapplicable to analysis radiochemical purity of labeledcompounds especially for the situations of unsufficient reduction of  ̄(186)ReO_4 and low labeling rate. Thecomplex column chromatographic system used for the determination of radiochemical purity is both simple and rapid. Animal experiments in rats indicate that the radioactive absorption of thyroid and liverfor purified  ̄(186)Re (Sn)-HEDP is obviously less than unpurified one.
出处 《同位素》 CAS 北大核心 1995年第4期210-216,共7页 Journal of Isotopes
关键词 HEDP 色层分析 高压液相色谱 镭186 bone tumor Rhenium-186 HEDP chromatapraphical analysis HPLC
  • 相关文献

同被引文献11

  • 1刘跃民,马崇智,卢玉楷,唐谨,战军.骨肿瘤治疗剂^(153)Sm-EDTMP的研究[J].同位素,1993,6(1):1-6. 被引量:7
  • 2赵葵,程维荷,沈文华,闻世凤,黄学军,李林法,石根明,胡志强.^(153)钐-乙二胺四甲撑膦酸治疗转移性骨癌临床观察[J].实用肿瘤杂志,1996,11(1):27-28. 被引量:4
  • 3Robinson RG, Preston DF, Schiefelbein M. Strontium 89 Therapy for the Palliation of Pain Dueto Osseous Metastases[J]. JAMA, 1995,274 (5) ..420-424.
  • 4Robinson RG. Systemic Radioisotopic Therapy of Primary and Metastatic Bone Cancer[J]. JNM,1990,31(8):1 326-1 327.
  • 5Blake GM, Zivanovic MA, McEwan A J, et al.Sr-89 Therapy:Strontium-89 Kinetic in Disseminated Carcinoma of the Prostate[J]. Eur J Nucl Med, 1986,12:447-454.
  • 6Crawford ED, Balmer C, Kozlowski JM,et al.The Use of Strontiunm-89 for Palliation of Pain From Bone Metastases Associated With Hormone Refractory Prostate Cancer[J]. Urology, 1994,44:481-485.
  • 7Porter AT,McEwan AJB, Powe JE,et al. Results of a Randomized Phase-Ⅱ Trial to Evaluate the Efficacy of Strontium-89 Adjuvant to Local Field External Beam Irradiation in the Management of Endocrine Resistant Metastatic Prostate Cancer[J]. Int J Radiation Oncology Biol Phys, 1993,25:805-813.
  • 8Robinson RG, Preston DF, Spicer JA,et al. Radionuclide Therapy of Intractable Bone Pain :Emphasis on Strontium 89[J]. Semin NM, 1992,22:28-32.
  • 9曾琴,金稚奎,张强,陈少萍.^(89)Sr治疗转移性骨癌的初步临床应用[J].南京医科大学学报(自然科学版),1997,17(6):628-630. 被引量:21
  • 10杜进,金小海,白宏升,刘跃民,陈大明,王凡.天然靶制备 ^(153)Sm 照射条件研究[J].原子能科学技术,1998,32(1):54-58. 被引量:1

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部